医学综述
醫學綜述
의학종술
Medical Recapitulate
2015年
21期
4001-4003
,共3页
功能性消化不良%度洛西汀%莫沙必利
功能性消化不良%度洛西汀%莫沙必利
공능성소화불량%도락서정%막사필리
Functional dyspepsia%Duloxetine%Mosapride
目的：探讨度洛西汀联合莫沙必利治疗功能性消化不良（ FD ）的临床效果。方法选择2013年3月至2014年3月来东南大学医学院附属江阴医院就诊的80例FD患者，采用随机数字表法分为联合组和莫沙必利组，每组40例。莫沙必利组患者在餐前30 min 口服莫沙必利5 mg，每日3次；联合组患者在莫沙必利组治疗的基础上早餐后30 min 口服度洛西汀肠溶胶囊60 mg，每日1次，两组患者均治疗6周。治疗结束后比较两组患者的症状积分、疗效以及汉密尔顿焦虑量表（ HAMA）评分、汉密尔顿抑郁量表（ HAMD）评分，记录两组患者的不良反应发生情况。结果治疗后两组患者的症状积分均较治疗前显著降低（ t＝8.066，3.584，P＜0.05），且联合组患者的症状积分[（5.28±2.32）分]显著低于莫沙必利组[（7.96±2.68）分]（t＝3.778，P＜0.05），其症状积分改善率[（42.56±14.35）％]显著高于莫沙必利组[（29.12±8.59）％]（ t＝4.017，P ＜0.05）；联合组的疗效显著优于莫沙必利组（U＝47.50，P＜0.05）；治疗后联合组患者的 HAMA评分和 HAMD评分分别为（7.72±2.37）分、（8.88±2.03）分，莫沙必利组为（10.44±2.76）分、（14.36±4.41）分，两组患者的评分均较治疗前显著降低，且联合组患者评分显著低于莫沙必利组（ P＜0.05）。两组不良反应发生率比较差异无统计学意义（ P＞0.05）。结论度洛西汀联合莫沙必利能显著提高 FD的治疗效果，改善患者抑郁、焦虑症状评分。
目的：探討度洛西汀聯閤莫沙必利治療功能性消化不良（ FD ）的臨床效果。方法選擇2013年3月至2014年3月來東南大學醫學院附屬江陰醫院就診的80例FD患者，採用隨機數字錶法分為聯閤組和莫沙必利組，每組40例。莫沙必利組患者在餐前30 min 口服莫沙必利5 mg，每日3次；聯閤組患者在莫沙必利組治療的基礎上早餐後30 min 口服度洛西汀腸溶膠囊60 mg，每日1次，兩組患者均治療6週。治療結束後比較兩組患者的癥狀積分、療效以及漢密爾頓焦慮量錶（ HAMA）評分、漢密爾頓抑鬱量錶（ HAMD）評分，記錄兩組患者的不良反應髮生情況。結果治療後兩組患者的癥狀積分均較治療前顯著降低（ t＝8.066，3.584，P＜0.05），且聯閤組患者的癥狀積分[（5.28±2.32）分]顯著低于莫沙必利組[（7.96±2.68）分]（t＝3.778，P＜0.05），其癥狀積分改善率[（42.56±14.35）％]顯著高于莫沙必利組[（29.12±8.59）％]（ t＝4.017，P ＜0.05）；聯閤組的療效顯著優于莫沙必利組（U＝47.50，P＜0.05）；治療後聯閤組患者的 HAMA評分和 HAMD評分分彆為（7.72±2.37）分、（8.88±2.03）分，莫沙必利組為（10.44±2.76）分、（14.36±4.41）分，兩組患者的評分均較治療前顯著降低，且聯閤組患者評分顯著低于莫沙必利組（ P＜0.05）。兩組不良反應髮生率比較差異無統計學意義（ P＞0.05）。結論度洛西汀聯閤莫沙必利能顯著提高 FD的治療效果，改善患者抑鬱、焦慮癥狀評分。
목적：탐토도락서정연합막사필리치료공능성소화불량（ FD ）적림상효과。방법선택2013년3월지2014년3월래동남대학의학원부속강음의원취진적80례FD환자，채용수궤수자표법분위연합조화막사필리조，매조40례。막사필리조환자재찬전30 min 구복막사필리5 mg，매일3차；연합조환자재막사필리조치료적기출상조찬후30 min 구복도락서정장용효낭60 mg，매일1차，량조환자균치료6주。치료결속후비교량조환자적증상적분、료효이급한밀이돈초필량표（ HAMA）평분、한밀이돈억욱량표（ HAMD）평분，기록량조환자적불량반응발생정황。결과치료후량조환자적증상적분균교치료전현저강저（ t＝8.066，3.584，P＜0.05），차연합조환자적증상적분[（5.28±2.32）분]현저저우막사필리조[（7.96±2.68）분]（t＝3.778，P＜0.05），기증상적분개선솔[（42.56±14.35）％]현저고우막사필리조[（29.12±8.59）％]（ t＝4.017，P ＜0.05）；연합조적료효현저우우막사필리조（U＝47.50，P＜0.05）；치료후연합조환자적 HAMA평분화 HAMD평분분별위（7.72±2.37）분、（8.88±2.03）분，막사필리조위（10.44±2.76）분、（14.36±4.41）분，량조환자적평분균교치료전현저강저，차연합조환자평분현저저우막사필리조（ P＜0.05）。량조불량반응발생솔비교차이무통계학의의（ P＞0.05）。결론도락서정연합막사필리능현저제고 FD적치료효과，개선환자억욱、초필증상평분。
Objective To investigate the clinical effects of duloxetine combined with mosapride on patients with functional dyspepsia.Methods Total of 80 patients with functional dyspepsia from Southeast University Medical College Affiliated Jiangyin Hospital during Mar.2013 and Mar.2014were selected,and then randomly divided into combined group and mosapride group ,40 cases in each group.In the mosapride group,the patients received oral mosapride 5 mg/time,3 times/d,30 min before a meal.Pateints in the com-bined group were given oral duloxetine 60 mg/times,1 time/d,on the basis of the mosapride group at 30 min after breakfast.Both groups were treated for 6 weeks.Symptom scores,efficacy and Hamilton anxiety scale (HAMA) score,Hamilton depression sale (HAMD) score of the two groups were compared,and the adverse effects were recorded.Results Symptom scores of the two groups were significantly lower than before treat-ment(t=8.066,3.584,P<0.05),and the combined group was significantly lower than the mosapride group [(5.28 ±2.32) vs (7.96 ±2.68)] (t =3.778,P <0.05),improvement rate of symptom scores of the combined group was (42.56 ±14.35)% and of the mosapride group was (29.12 ±8.59)%,the difference between the two groups was significant(t=4.017,P<0.05).The curative effect of the combined group was significantly higher than the mosapride group (U =47.50,P <0.05).HAMA scores and HAMD scores of the combined group were (7.72 ±2.37) and (8.88 ±2.03),which were significantly lower than those of the mosapride group[(10.44 ±2.76) and (14.36 ±4.41)](P<0.05).There was no statistically signifi-cant difference between the two groups on adverse reactions(P>0.05).Conclusion Duloxetine combined with mosapride can significantly improve the efficacy of functional dyspepsia ,and improve the depression and anxiety scores.
